First Italian Gene Therapy for Hemophilia B at the Polyclinic of Milan
Polyclinic of Milan (Ospedale Policlinico di Milano) posted on LinkedIn:
”The first gene therapy in Italy for the treatment of severe or moderately severe hemophilia B, a rare hereditary disease caused by the deficiency of coagulation factor IX, has been administered at the Polyclinic of Milan. The therapy, indicated only for adult patients, was performed in the Haemophilia Centre of the Polyclinic of Milan, directed by Flora Peyvandi, recognised as a national and international reference point for congenital haemorrhagic diseases and the Hub Centre of the Lombardy Region for the Congenital Haemorrhagic Diseases Network (MEC).
The treatment, recently authorized by the Italian Medicines Agency and now accessible through the National Health Service, consists of a single and unrepeatable infusion that allows the body to produce Factor IX independently, significantly reducing the need for periodic infusions provided for by traditional replacement therapies.
Haemophilia B is an inherited genetic disorder characterised by the deficiency of Factor IX, a protein essential for blood clotting. Those affected have a high tendency to develop spontaneous bleeding or bleeding caused by minimal trauma, often localized in the joints and muscles, with the risk of chronic pain, progressive joint damage and significant limitations in daily life.
Through this result, the Polyclinic of Milan confirms its vocation to lead the introduction of advanced therapies in the public health system. In recent years, the Hospital has performed the first Italian gene therapy treatments for haemophilia A and has participated in international studies dedicated to rare coagulation diseases, integrating clinical activity, research and training.
“Gene therapy represents an important turning point in the evolution of the treatment of hemophilia B,” says Flora Peyvandi. For the first time, we have a treatment administered in a single infusion, capable of allowing patients to produce adequate levels of Factor IX and reducing the impact of the disease on daily life. It is a result that stems from the joint work of our professionals, institutions and patient associations, and which opens up new perspectives for the treatment of this disease”.
“The treatment of the first patient in Italy with gene therapy for haemophilia B testifies to the role of the Polyclinic of Milan as a public hospital capable of bringing innovations that really make a difference into clinical practice. Investing in skills, research and a multidisciplinary organization that values professionals means guaranteeing patients increasingly advanced care. This achievement represents a further step in our mission to offer everyone access to the best therapeutic opportunities available,” says CEO Matteo Stocco.”
Stay updated with Hemostasis Today.
-
Apr 23, 2026, 12:18Mona Ranade: A Contemporary Framework for Managing Right Heart Thrombus in PE
-
Apr 23, 2026, 11:59Strengthening Hemophilia Care Through Collaboration and Commitment in India at IHC X 2026 – Hemophilia Federation India
-
Apr 23, 2026, 08:16David Ferreira: Identifying the True Drivers of Recurrent Thrombosis
-
Apr 23, 2026, 08:05Hugo Antonio Romo Rubio: Biology, Function, and Updated Classification of von Willebrand Disease
-
Apr 23, 2026, 07:50Hassan Raza: A Smarter Risk Prediction in MPNs Using AI
-
Apr 23, 2026, 05:32Why TXA and rFVIIa Are Not Equivalent in Trauma Bleeding Control – RPTH Journal
-
Apr 23, 2026, 04:08Suraj Mali: Pune Team Initiative for World Hemophilia Day 2026 Advances Early Diagnosis in Hemophilia
-
Apr 23, 2026, 03:58Adam Ho: What Does It Actually Mean to ”Prevent” a Stroke?
-
Apr 23, 2026, 03:49Jakob Krebs Christensen: Mobile Stroke Units Bring Imaging and Treatment Directly to the Patient